Coronavirus | Health Technology Net

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic

BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively…

10 months ago

Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering

NEW YORK, NY / ACCESSWIRE / February 15, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering…

11 months ago

NanoViricides Has Filed its Quarterly Report – NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon

SHELTON, CT / ACCESSWIRE / February 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum…

11 months ago

Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering

NEW YORK, NY / ACCESSWIRE / February 13, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering…

11 months ago

Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments

Jordyn Tarazi joins as Vice President, Investor Relations and Corporate Communications Nikhil Aneja, CPA, CA appointed as Vice President, Finance…

11 months ago

Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides – NV-387 Could be As Revolutionary as Antibiotics

SHELTON, CT / ACCESSWIRE / February 1, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development…

11 months ago

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset

Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize…

11 months ago

Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found

SHELTON, CT / ACCESSWIRE / January 29, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development…

11 months ago

CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and…

11 months ago

Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

- 10,000-subject Phase 2b study would evaluate Vaxart’s next generation oral pill XBB COVID-19 vaccine against an approved mRNA vaccine…

11 months ago